OBJECTIVE: To examine the prognostic value of select biobehavioral factors in patients with chronic obstructive pulmonary disease (COPD) in a secondary analysis of participants from the INSPIRE-II trial. METHODS: Three hundred twenty-six outpatients with COPD underwent assessments of pulmonary function, physical activity, body mass index, inflammation, pulmonary symptoms, depression, and pulmonary quality of life and were followed up for up to 5.4 years for subsequent clinical events. The prognostic value of each biobehavioral factor, considered individually and combined, also was examined in the context of existing Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011 risk stratification. RESULTS: Sixty-nine individuals experienced a hospitalization or died over a mean follow-up period of 2.4 (interquartile range = 1.6) years. GOLD classification was associated with an increased risk of clinical events (hazard ratio [HR] = 2.72 [95% confidence interval = 1.63-4.54], per stage); 6-minute walk (HR = 0.50 [0.34-0.73] per 500 ft), total steps (HR = 0.82 [0.71-0.94] per 1000 steps), high-sensitivity C-reactive protein (HR = 1.44 [1.01-2.06] per 4.5 mg/l), depression (HR = 1.12 [1.01-1.25] per 4 points), and pulmonary quality of life (HR = 1.73 [1.14-2.63] per 25 points) were each predictive over and above the GOLD assessment. However, only GOLD group and 6-minute walk were predictive of all-cause mortality and COPD hospitalization when all biobehavioral variables were included together in a multivariable model. CONCLUSIONS: Biobehavioral factors provide added prognostic information over and above measures of COPD severity in predicting adverse events in patients with COPD.
OBJECTIVE: To examine the prognostic value of select biobehavioral factors in patients with chronic obstructive pulmonary disease (COPD) in a secondary analysis of participants from the INSPIRE-II trial. METHODS: Three hundred twenty-six outpatients with COPD underwent assessments of pulmonary function, physical activity, body mass index, inflammation, pulmonary symptoms, depression, and pulmonary quality of life and were followed up for up to 5.4 years for subsequent clinical events. The prognostic value of each biobehavioral factor, considered individually and combined, also was examined in the context of existing Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011 risk stratification. RESULTS: Sixty-nine individuals experienced a hospitalization or died over a mean follow-up period of 2.4 (interquartile range = 1.6) years. GOLD classification was associated with an increased risk of clinical events (hazard ratio [HR] = 2.72 [95% confidence interval = 1.63-4.54], per stage); 6-minute walk (HR = 0.50 [0.34-0.73] per 500 ft), total steps (HR = 0.82 [0.71-0.94] per 1000 steps), high-sensitivity C-reactive protein (HR = 1.44 [1.01-2.06] per 4.5 mg/l), depression (HR = 1.12 [1.01-1.25] per 4 points), and pulmonary quality of life (HR = 1.73 [1.14-2.63] per 25 points) were each predictive over and above the GOLD assessment. However, only GOLD group and 6-minute walk were predictive of all-cause mortality and COPD hospitalization when all biobehavioral variables were included together in a multivariable model. CONCLUSIONS: Biobehavioral factors provide added prognostic information over and above measures of COPD severity in predicting adverse events in patients with COPD.
Authors: Peter Lange; Jacob Louis Marott; Jørgen Vestbo; Kim Rose Olsen; Truls Sylvan Ingebrigtsen; Morten Dahl; Børge Grønne Nordestgaard Journal: Am J Respir Crit Care Med Date: 2012-09-20 Impact factor: 21.405
Authors: Jørgen Vestbo; Suzanne S Hurd; Alvar G Agustí; Paul W Jones; Claus Vogelmeier; Antonio Anzueto; Peter J Barnes; Leonardo M Fabbri; Fernando J Martinez; Masaharu Nishimura; Robert A Stockley; Don D Sin; Roberto Rodriguez-Roisin Journal: Am J Respir Crit Care Med Date: 2012-08-09 Impact factor: 21.405
Authors: MeiLan K Han; Hana Muellerova; Douglas Curran-Everett; Mark T Dransfield; George R Washko; Elizabeth A Regan; Russell P Bowler; Terri H Beaty; John E Hokanson; David A Lynch; Paul W Jones; Antonio Anzueto; Fernando J Martinez; James D Crapo; Edwin K Silverman; Barry J Make Journal: Lancet Respir Med Date: 2012-09-03 Impact factor: 30.700
Authors: Ane Johannessen; Roy M Nilsen; Michael Storebø; Amund Gulsvik; Tomas Eagan; Per Bakke Journal: Am J Respir Crit Care Med Date: 2013-07-01 Impact factor: 21.405
Authors: Peter J Barnes; Badrul Chowdhury; Sergei A Kharitonov; Helgo Magnussen; Clive P Page; Dirkje Postma; Marina Saetta Journal: Am J Respir Crit Care Med Date: 2006-03-23 Impact factor: 21.405
Authors: Joan B Soriano; Inmaculada Alfageme; Pere Almagro; Ciro Casanova; Cristobal Esteban; Juan J Soler-Cataluña; Juan P de Torres; Pablo Martinez-Camblor; Marc Miravitlles; Bartolome R Celli; Jose M Marin Journal: Chest Date: 2013-03 Impact factor: 9.410
Authors: Victor Pinto-Plata; Ciro Casanova; Hana Müllerova; Juan P de Torres; Henneth Corado; Nerea Varo; Elizabeth Cordoba; Salah Zeineldine; Hildegarde Paz; Rebeca Baz; Miguel Divo; Felipe Cortopassi; Bartolome R Celli Journal: Respir Res Date: 2012-08-20
Authors: Jilles M Fermont; Katya L Masconi; Magnus T Jensen; Renata Ferrari; Valéria A P Di Lorenzo; Jacob M Marott; Philipp Schuetz; Henrik Watz; Benjamin Waschki; Hana Müllerova; Michael I Polkey; Ian B Wilkinson; Angela M Wood Journal: Thorax Date: 2019-01-07 Impact factor: 9.139
Authors: James A Blumenthal; Patrick J Smith; Andrew Sherwood; Stephanie Mabe; Laurie Snyder; Courtney Frankel; Daphne C McKee; Natalie Hamilton; Francis J Keefe; Sheila Shearer; Jeanne Schwartz; Scott Palmer Journal: Transplant Direct Date: 2020-02-18